This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Labcorp Stock Climbs 25.6% This Year: What's Driving the Surge?
by Zacks Equity Research
LH stock surges 25.6% this year, powered by specialty testing expansion, key acquisitions and solid financials.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
DGX Stock Up on New Blood Test Development Deal With MD Anderson
by Zacks Equity Research
DGX stock rises on a new partnership with MD Anderson to develop a blood test targeting multiple cancer risks.
QGEN Stock Rises in After Market Following Partnership With Incyte
by Zacks Equity Research
QIAGEN teams up with Incyte to develop NGS-based companion diagnostics for blood cancers.
Should You Hold Myriad Genetics Stock in Your Portfolio Right Now?
by Zacks Equity Research
MYGN sees growth in oncology and women's health testing, but GeneSight coverage loss clouds the near-term outlook.
Zacks.com featured highlights include Popular, Affiliated Managers, Astronics and Phibro Animal Health
by Zacks Equity Research
Popular, AMG, Astronics and Phibro are trading near 52-week highs with strong momentum and room for more upside.
Should You Add QIAGEN Stock to Your Portfolio for Now?
by Zacks Equity Research
QGEN rides on test menu growth, strategic partnerships, and strong solvency, despite macro and market headwinds.
PAHC vs. BSX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PAHC vs. BSX: Which Stock Is the Better Value Option?
4 Stocks Trading Near 52-Week High With More Upside Potential
by Vasundhara Sawalka
Stocks like BPOP, AMG, ATRO and PAHC are seeing price strength and have a high chance of carrying the momentum forward.
Thermo Fisher Stock Hurt by Macroeconomic Woes, Tough Competition
by Zacks Equity Research
TMO grapples with macro pressures, rising expenses and fierce competition, but bets on acquisitions to fuel recovery.
Are Investors Undervaluing Phibro Animal Health (PAHC) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why You Should Retain AMED Stock in Your Portfolio for Now
by Zacks Equity Research
Amedisys' high Quality of Patient Care and Patient Satisfaction star ratings bring optimism to investors. Yet, a dull macroeconomic condition adds to the worry.
Brainsway Ltd. Sponsored ADR (BWAY) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Brainsway (BWAY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's Why You Should Retain PODD Stock in Your Portfolio Now
by Zacks Equity Research
Insulet's Omnipod 5 gains traction with global expansion and rising Type 2 adoption despite economic and competitive hurdles.
Should You Continue to Hold Prestige Consumer Stock in Your Portfolio?
by Zacks Equity Research
PBH rides strong on e-commerce gains and brand innovations, but debt load and forex risks cast a shadow on future growth.
Bruker Stock Set to Gain From Acquisition of Austria's biocrates
by Zacks Equity Research
BRKR strengthens its MS-based metabolomics platform with the biocrates deal, boosting investor sentiment.
PEN Stock Rises Following the Launch of Ruby XL System
by Zacks Equity Research
Penumbra launches FDA-cleared Ruby XL System to bring advanced coil technology to high-flow embolization procedures.
Phibro (PAHC) Up 7.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Phibro Animal Health (PAHC) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Is it Apt to Retain Omnicell Stock in Your Portfolio Now?
by Zacks Equity Research
OMCL stays on investors' radar due to its strong 2025 growth targets with automation and tech services, but faces margin risks from macro and competitive headwinds.
Should You Continue to Hold EXAS Sciences Stock in Your Portfolio?
by Zacks Equity Research
EXAS rides on strong Cologuard and Oncotype DX growth, but rising costs and high debt may test its staying power.
Should You Continue to Hold Labcorp Stock in Your Portfolio?
by Zacks Equity Research
LH's growth focus and financial strength look promising, but can it navigate rising competition and macro headwinds?
Zacks.com featured highlights Urban Outfitters, Phibro Animal Health and Strattec Security
by Zacks Equity Research
Urban Outfitters, Phibro, and Strattec defy trade jitters with strong earnings surprises and rising price momentum.
3 Stocks Showing Positive Momentum Despite Trade Tensions
by Tirthankar Chakraborty
Urban Outfitters, Phibro Animal Health and Strattec Security are defying trade-driven volatility, showing strong momentum and standout earnings surprises.
TMO Launches Next-Generation Mass Spectrometers: Stock to Gain?
by Zacks Equity Research
Thermo Fisher debuts two advanced MSs, Orbitrap Astral Zoom and Orbitrap Excedion Pro, to accelerate precision medicine and drug discovery breakthroughs.